Comments for MRK - Stockpickr! Your Source for Stock Ideas

Comments for MRK

Added By	Comments	Type	Date Added
RhinoStocks	Short Interest Ratio: 10.73	Love	November 11, 2009
Debbie Merhman	undervalued	Love	October 27, 2009
Yobo3	Former employer, consistent dividends	Love	October 09, 2009
RoyMac	Steady Growth	Love	September 16, 2009
barrons3	Not that I want us to be led by Merck (MRK) or by Johnson & Johnson (JNJ) -- it is just that the $3 spike in oil feels incredibly phony, just one of those oddities that seems entirely asset-class driven, not demand driven, a function of a falling dollar and money exiting toward a commodity that is not in that much demand.	Love	September 10, 2009
Pg11229A	good pharma company	Love	September 04, 2009
judynigel	got alot	Love	August 19, 2009
cariblady104@yahoo.com	pharmacy and pays dividend	Love	August 18, 2009
barrons3	As for the rest of Big Pharma, Ryan sees dividends staying flat because of merger loans. "While making acquisitions, Merck [MRK], Eli Lilly [LLY] and Bristol-Myers Squibb [BMY] have not reduced dividends; however, we suspect that this means that they are unlikely to increase them much in the future."	Love	August 15, 2009
John.Orzol	Solid stock	Love	August 12, 2009
barrons3	Is this market a referendum on President Obama? When I see Merck (MRK) and Pfizer (PFE) go up and UnitedHealth (UNH) and Aetna (AET) sneaking higher, I think, wait a second -- we are smelling repudiation here.	Love	July 23, 2009
barrons3	When you see Gilead (GILD), Coca-Cola (KO), Abbott Laboratories (ABT) and Merck (MRK) down on this otherwise perfect day, you have to recognize that consistency is so out of favor as to make safety be the killer -- the true generator of underperformance.	Love	June 04, 2009
Stockpickr Staff	"When you see Gilead (GILD), Coca-Cola (KO), Abbott Laboratories (ABT) and Merck (MRK) down on this otherwise perfect day, you have to recognize that consistency is so out of favor as to make safety be the killer -- the true generator of underperformance." (<a href="http://jimcramer.rmblogs.thestreet.com/entry.aspx?q=c0de89ca-5971-4549-98b6-9c1b00f99015" target="_blank">"Saftey Last," 6-1-09</a>)	Love	June 02, 2009
ElectionStocks	Big pharma is almost sure to take a hit from any sort of reform.	Hate	May 21, 2009
Patrick H. Peters, Jr., MD	Totally mismanaged the research of Viox and Vytorin. Dinosaur stuck in a tar pit!	Hate	May 20, 2009
barrons3	I think the soft-goods rotation is more of a statement about the dollar than anything else -- we hit seven-week lows yesterday on our currency. That could be the answer to the conundrum about how we could be in "recovery" mode and yet still have the rally by the likes of Coke (KO), Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE).	Love	May 14, 2009
barrons3	On the downside, the losers tell a similar story, with defensive drug stocks like Pfizer (PFE) and Merck (MRK) both down heartily as investor switch gears into growth stocks again.	Love	April 30, 2009
Sinvestor	investment solid dividend	Love	March 20, 2009
barrons3	Merck (MRK) has patent issues, and the new Supreme Court decision makes its products, particularly its vaccines, a free-fire zone. Also, this is the company that could be one of the most hurt by Obama's pitting of drug companies against each other to get a great price for the government. Chop a multiple point off it and cut earnings by a quarter, and let's call it $15.	Love	March 12, 2009
sarah z	“Talk about the opposite of President Clinton. Both Clinton and Obama campaigned on the idea of reining in health care costs. Clinton even went so far as to go to Merck's (MRK) headquarters and rail against big pharma, something that exceeded any of the tough talk of Obama. But once Clinton came in, his health care plans were so diffuse and convoluted, it turned out to be all bluster. The stocks rallied and rallied, his bashing turned out to be a great opportunity to buy just about every private enterprise having to do with health care, from devices and pharmaceuticals to health maintenance organizations and cost containers. Wow, what a difference! Obama, it turns out, meant it! He's waging war against the health maintenance organizations, the cost containers. He's changing the rules on Medicare in a way that Humana (HUM) or UnitedHealth (UNH) never thought was possible. He's destroying the margins of Aetna (AET) and Cigna (CI). These companies, particularly Humana, have this tremendous Medicare senior plans where they were just raking it in and were subsidized by the government. So now they are coming for everything in the sector, as reimbursements could be cut for everything. That means some pain in Genzyme (GENZ), which has high-priced drugs that may not be protected. And some heart assists, like St. Jude (STJ), which have been doing excellently, are getting killed. Drug stocks -- no one thinks they can get through unscathed now. It didn't help that Express Scripts (ESRX) sees some weakness, as people might even be cutting back on taking drugs! Nasty. This group's been a lone winner. It might regain luster if we can find out that the war is just against this health care cost containment group, which Obama said didn't cut costs or contain anything. In fact, he came perilously close to saying that this group is just a tax on the system, not unlike Sallie Mae (SLM), which he wants to destroy because it would be better to give loans direct from the government. Look at that stock! I have felt that Obama thought that the Aetnas and the UnitedHealths should be nonprofits. He is sure making it that way. Health care had been a safe haven from the awful economy. That might be true, but now we see it's no safe haven from Obama. The worst dreams of the capitalists are being realized; stocks just got even more unsafe than they were before this budget came out.”	Love	February 26, 2009
barrons3	Talk about the opposite of President Clinton. Both Clinton and Obama campaigned on the idea of reining in health care costs. Clinton even went so far as to go to Merck's (MRK) headquarters and rail against big pharma, something that exceeded any of the tough talk of Obama.	Love	February 26, 2009
sarah z	From a recent Mad Money show:"It's not my favorite pharma, but I like healthcare. I prefer Bristol-Myers Squibb (BMY) and Abbott Laboratories (ABT) more though."	Love	February 23, 2009
barrons3	The drug sector is well represented with industry leaders Merck, Bristol-Myers, Lilly and Pfizer. Dividends at all four look secure, although future payout increases could be muted by modest annual profit growth. The new Pfizer dividend of 64 cents annually, for a 4.5% yield, looks safe at just 30% of projected 2009 earnings. The negative investor reaction to the Pfizer payout cut may make other drug makers wary of reducing dividends.	Love	February 14, 2009
barrons3	Cramer said the good "banks" are companies like Schering-Plough (SGP), which reported a huge quarter and has money to burn. Merck (MRK) also reported a gigantic quarter and is flush with cash to buy other companies or its own stock.	Love	February 05, 2009
barrons3	We had good numbers from Schering-Plough (SGP) and Merck (MRK) but not this good! Abbott Labs (ABT) is on a breakout. Gilead (GILD) was looking lower, and then boom, Daschle's gone.	Love	February 05, 2009
sarah z	“Is this Tom Daschle rally? Drug stocks have been on fire since the news that public pharma enemy No. 1 is gone. We had good numbers from Schering-Plough (SGP) and Merck (MRK) but not this good! Abbott Labs (ABT) is on a breakout. Gilead (GILD) was looking lower, and then boom, Daschle's gone. Next thing you know, you have a leader, and that leader is taking up a lot of the soft goods side! The drugs do have pin action today, something that can happen when you have a group breaking out this hard. You can see another leg higher for UnitedHealth Group (UNH), I mentioned Medco Health Solutions (MHS) before, and now we see the Colgates (CL), Procters (PG) and Avons (AVP) moving on up. None of this was happening before the Daschle withdrawal! He's a catalyst, a catalyst because he didn't let the door hit him on the way out.	Love	February 03, 2009
barrons3	So now we hate the drug stocks. Now we think they aren't delivering on the numbers. We are selling Merck (MRK) and Schering (SGP) and we hate Johnson & Johnson (JNJ).	Love	January 22, 2009
High Dividends	0.1%	Love	January 12, 2009
barrons3	Commenting on the uptick the last couple of days in Pfizer (PFE) and Merck (MRK) shares, Najarian said a lot of investors who have been chasing the dividend of those stocks should be careful. "We're looking for growth here and neither of them has put much out there to impress the Street," he said. Najarian said Merck at least has signaled a jump into the pharmaceutical area, which he regards as "positive."	Love	December 31, 2008
Dline2	Probably should of gone with LLY. But pretty solid	Love	December 23, 2008